Clinical features in coronavirus disease 2019 (COVID-19) patients with early clearance and prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA
2021 Annals of Translational Medicine. All rights reserved..
BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID-19), the pattern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA shedding has not been well characterized.
METHODS: In our study, 652 patients in Wuhan Designated Hospital were recruited, and their clinical and laboratory findings were extracted and analyzed.
RESULTS: The median duration of SARS-CoV-2 RNA detection was 23 days [interquartile range (IQR), 18 days] from symptom onset. Compared to patients with early viral RNA clearance (<23 days after illness onset), we found that patients with late viral RNA clearance (≥23 days) had a higher proportion of clinical features, as follows: symptoms, including fever, dry cough, and sputum production; comorbidities, including hypertension, chronic kidney disease, uremia, chronic liver disease, anemia, hyperlipidemia, and bilateral lung involvement; complications, such as liver injury; delayed admission to hospital; laboratory parameters at baseline, including higher eosinophils, uric acid, cholesterol, triglycerides, and lower hemoglobin; and less treatment with arbidol, chloroquine, or any antivirals. After generalized linear regression, prolonged SARS-CoV-2 RNA shedding was independently associated with younger age; delayed admission to hospital; symptoms including fever, shivering, and sputum production; comorbidities including hypertension, diabetes, cardiovascular disease, anemia, hyperlipidemia, uremia, and lung involvement; and higher alanine aminotransferase (ALT), uric acid, and cholesterol levels at baseline.
CONCLUSIONS: In conclusion, the factors mentioned above are associated with the negative conversion of SARS-CoV-2 RNA. A deeper insight into virological dynamics will be helpful for establishing patient discharge and quarantine release criteria.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Annals of translational medicine - 9(2021), 8 vom: 11. Apr., Seite 665 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhou, Yan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease 2019 (COVID-19) |
|---|
| Anmerkungen: |
Date Revised 23.04.2022 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/atm-21-445 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325387303 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325387303 | ||
| 003 | DE-627 | ||
| 005 | 20231225192328.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/atm-21-445 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1084.xml |
| 035 | |a (DE-627)NLM325387303 | ||
| 035 | |a (NLM)33987363 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Yan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical features in coronavirus disease 2019 (COVID-19) patients with early clearance and prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2021 Annals of Translational Medicine. All rights reserved. | ||
| 520 | |a BACKGROUND: Since the outbreak of coronavirus disease 2019 (COVID-19), the pattern of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA shedding has not been well characterized | ||
| 520 | |a METHODS: In our study, 652 patients in Wuhan Designated Hospital were recruited, and their clinical and laboratory findings were extracted and analyzed | ||
| 520 | |a RESULTS: The median duration of SARS-CoV-2 RNA detection was 23 days [interquartile range (IQR), 18 days] from symptom onset. Compared to patients with early viral RNA clearance (<23 days after illness onset), we found that patients with late viral RNA clearance (≥23 days) had a higher proportion of clinical features, as follows: symptoms, including fever, dry cough, and sputum production; comorbidities, including hypertension, chronic kidney disease, uremia, chronic liver disease, anemia, hyperlipidemia, and bilateral lung involvement; complications, such as liver injury; delayed admission to hospital; laboratory parameters at baseline, including higher eosinophils, uric acid, cholesterol, triglycerides, and lower hemoglobin; and less treatment with arbidol, chloroquine, or any antivirals. After generalized linear regression, prolonged SARS-CoV-2 RNA shedding was independently associated with younger age; delayed admission to hospital; symptoms including fever, shivering, and sputum production; comorbidities including hypertension, diabetes, cardiovascular disease, anemia, hyperlipidemia, uremia, and lung involvement; and higher alanine aminotransferase (ALT), uric acid, and cholesterol levels at baseline | ||
| 520 | |a CONCLUSIONS: In conclusion, the factors mentioned above are associated with the negative conversion of SARS-CoV-2 RNA. A deeper insight into virological dynamics will be helpful for establishing patient discharge and quarantine release criteria | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a negative conversion | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a viral RNA clearance | |
| 650 | 4 | |a viral shedding | |
| 700 | 1 | |a Ding, Fengming |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Wuping |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Yishu |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Pengyu |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Dongning |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Aihua |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Zengchao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Min |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of translational medicine |d 2013 |g 9(2021), 8 vom: 11. Apr., Seite 665 |w (DE-627)NLM23455374X |x 2305-5839 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:8 |g day:11 |g month:04 |g pages:665 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/atm-21-445 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 8 |b 11 |c 04 |h 665 | ||